Polyphor announces successful end of phase II meeting with FDA for Murepavadin in nosocomial pneumonia

May 19, 2017
Polyphor Ltd

Allschwil, Switzerland, May 19, 2017 – Polyphor Ltd., a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, today announced the receipt of a positive guidance from the end of phase II clinical meeting with the US Food and Drug Administration (FDA) for its leading product candidate, Murepavadin, for the treatment of patients with nosocomial pneumonia (Ventilator-associated and hospital-acquired pneumonia; VAP/ HAP).

Press Release available here: